Ionis Pharmaceuticals News

Piper Sandler Remains a Buy on Ionis Pharmaceuticals (IONS)

TipRanksApr 26 07:50 ET

Ionis Publishes 2023 Corporate Responsibility Report

Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring

Ionis PharmaceuticalsApr 25 07:00 ET

Ionis to Hold First Quarter 2024 Financial Results Webcast

Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif., April 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live we

PR NewswireApr 23 07:05 ET

Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints

Seeking AlphaApr 19 17:10 ET

Polycythemia Pipeline Insight 2024, Featuring Protagonist Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, Imago BioSciences, Incyte, Italfarmaco, Lynk and Promedior

Yahoo FinanceApr 18 03:53 ET

Form 144 | Ionis Pharmaceuticals(IONS.US) Officer Proposes to Sell 168.25K in Common Stocks

SEC FILLINGS DISCLOSED/ Apr 16, $Ionis Pharmaceuticals(IONS.US)$ Officer Baroldi Joseph intends to sell 4,006 shares of its common stock on Apr 16, with a total market value of approximately $168.25K.

moomoo NewsApr 16 21:02 ET

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Right But Growth Is Lacking

You may think that with a price-to-sales (or "P/S") ratio of 7.7x Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a stock worth checking out, seeing as almost half of all the Biotechs companies in the Un

Simply Wall StApr 15 11:23 ET

Wolfe Upgrades Ionis to Outperform, Cites Upcoming Catalysts

Seeking AlphaApr 10 12:03 ET

Express News | Wolfe Research Upgrades Ionis Pharmaceuticals to Outperform

Moomoo 24/7Apr 10 04:32 ET

Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra

Seeking AlphaApr 9 10:03 ET

Oppenheimer Raises Ionis Pharmaceuticals' Price Target to $75 From $72, Maintains Outperform Rating

Ionis Pharmaceuticals (IONS) has an average rating of Outperform and price targets ranging from $29 to $85, according to analysts polled by Capital IQ. Price: 43, Change: +0.76, Percent Change: +1.8

MT NewswiresApr 9 09:08 ET

Ionis Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Ionis Pharmaceuticals Is Maintained at Outperform by Oppenheimer

Dow JonesApr 9 08:38 ET

Ionis Pharmaceuticals (IONS) Gets a Buy From Piper Sandler

TipRanksApr 9 07:06 ET

Express News | Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

Moomoo 24/7Apr 9 06:34 ET

Ionis Pharmaceuticals Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 42.05% Needham → $60 Reiterates Buy → Buy 03/06/2024 70.45% Oppenheimer $65 → $72 Maintains Out

BenzingaApr 9 06:33 ET

Analysts Are Bullish on Top Healthcare Stocks: Ionis Pharmaceuticals (IONS), Intuitive Surgical (ISRG)

TipRanksApr 8 19:40 ET

Ionis Experimental Drug Meets Key Goal in Familial Chylomicronemia Study

Seeking AlphaApr 8 10:16 ET

Stifel Nicolaus Keeps Their Hold Rating on Ionis Pharmaceuticals (IONS)

TipRanksApr 8 07:15 ET

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ionis Pharmaceuticals (IONS) and Medtronic (MDT)

TipRanksApr 8 05:50 ET

Buy Rating on Ionis Pharmaceuticals: Promising Clinical Data and Strategic Market Positioning for Olezarsen

TipRanksApr 8 05:47 ET